Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
Quinazolinone-Dihydropyrano[3,2-B]Pyran Hybrids As New Α-Glucosidase Inhibitors: Design, Synthesis, Enzymatic Inhibition, Docking Study and Prediction of Pharmacokinetic Publisher Pubmed



Sherafati M1 ; Mirzazadeh R2 ; Barzegari E3 ; Mohammadikhanaposhtani M4 ; Azizian H5 ; Sadegh Asgari M6 ; Hosseini S7 ; Zabihi E4 ; Mojtabavi S8 ; Ali Faramarzi M8 ; Mahdavi M1 ; Larijani B1 ; Rastegar H9 ; Hamedifar H10 Show All Authors
Authors
  1. Sherafati M1
  2. Mirzazadeh R2
  3. Barzegari E3
  4. Mohammadikhanaposhtani M4
  5. Azizian H5
  6. Sadegh Asgari M6
  7. Hosseini S7
  8. Zabihi E4
  9. Mojtabavi S8
  10. Ali Faramarzi M8
  11. Mahdavi M1
  12. Larijani B1
  13. Rastegar H9
  14. Hamedifar H10
  15. Hamed Hajimiri M11

Source: Bioorganic Chemistry Published:2021


Abstract

A series of new quinazolinone-dihydropyrano[3,2-b]pyran derivatives 10A-L were synthesized by simple chemical reactions and were investigated for inhibitory activities against α-glucosidase and α-amylase. New synthesized compounds showed high α-glucosidase inhibition effects in comparison to the standard drug acarbose and were inactive against α-amylase. Among them, the most potent compound was compound 10L (IC50 value = 40.1 ± 0.6 µM) with inhibitory activity around 18.75-fold more than acarboase (IC50 value = 750.0 ± 12.5 µM). This compound was a competitive inhibitor into α-glucosidase. Our obtained experimental results were confirmed by docking studies. Furthermore, the cytotoxicity of the most potent compounds 10L, 10G, and 10N against normal fibroblast cells and in silico druglikeness, ADME, and toxicity prediction of these compounds were also evaluated. © 2021 Elsevier Inc.
Other Related Docs